Examples include anti-CD73 antibodies combined with traditional cancer treatments (i.e., chemotherapy, radiotherapy, immunotherapy, and targeted therapy)23, such as the anti-CD73 antibody BMS-986179 in combination with nivolumab (NCT02754141)24, the anti-CD73 antibody MEDI9447 (oleclumab) in combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib or the selective adenosine 2A receptor (A2AR) antagonist AZD4635 (NCT03381274)25, and oleclumab in combination with durvalumab (NCT02503774)26, which are currently in phase 1 and 2 clinical trials. Here, EGFR is linked to cancer.